Drugs / High-Titer COVID-19 Convalescent Plasma
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04361253 | Apr 2020 → Apr 2021 | COVID-19 | Brigham and Women's Hospital | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | High-Titer COVID-19 Convalescent Plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04361253 ↗ |
| Known as | HT-CCP | “High-Titer COVID-19 Convalescent Plasma (HT-CCP)” NCT04361253 ↗ |
| Modality | Protein / enzyme biologic | “plasma that contains a high amount of antibodies” NCT04361253 ↗ |